---
title: "Aidea Pharma: The full text of the 96-week study on Fubangde® SPRINT was published in BMC Medicine"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/260697344.md"
description: "Aidea Pharma announced on October 11th that the results of its self-developed anti-HIV drug Fubangde® SPRINT's Phase III clinical study have been published in BMC Medicine. This journal is a top medical journal with an impact factor of 9.4, and the influence of the published research results surpasses that of imported similar products"
datetime: "2025-10-11T00:13:11.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/260697344.md)
  - [en](https://longbridge.com/en/news/260697344.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/260697344.md)
---

# Aidea Pharma: The full text of the 96-week study on Fubangde® SPRINT was published in BMC Medicine

On October 11th, Aidea Pharma announced that the company's independently developed China's first "three-in-one" single-tablet combination innovative drug, the next-generation non-nucleoside combination formulation AINOMITE, has had its key Phase III clinical research results published in full in the flagship medical journal BMC Medicine, under the global academic publishing giant Springer Nature. This journal is a top-tier journal in the JCR and the Chinese Academy of Sciences' Zone 1, with a 5-year impact factor of 9.4. In addition, the influence of this publication has currently surpassed that of imported similar products

### Related Stocks

- [688488.CN](https://longbridge.com/en/quote/688488.CN.md)

## Related News & Research

- [El Niño Fears Push Coffee Prices Higher](https://longbridge.com/en/news/287248088.md)
- [Is RFK's 'carnivore diet' healthy? Here's what you need to know.](https://longbridge.com/en/news/286951172.md)
- [Is Gardening the Secret to Long-term Exercise?](https://longbridge.com/en/news/287245333.md)
- [Should You Be Adding Daewoong Pharmaceutical (KRX:069620) To Your Watchlist Today?](https://longbridge.com/en/news/286824214.md)
- [BYD is struggling to meet demand for new fast-charging EVs as orders reach 100K, 60K](https://longbridge.com/en/news/287109883.md)